ALNA Allena Pharma NASDAQ Pre-Mkt 06 Feb 2026: Vol 252.31M watch catalyst

ALNA stock is trading in the pre-market on 06 Feb 2026 at $0.075 with heavy turnover, 252,311,606 shares reported. Allena Pharmaceuticals, Inc. (ALNA) on the NASDAQ is drawing volume as traders react to microcap biotech positioning and pipeline updates. We look at price action, key ratios like EPS -0.638 and PB 0.13, and the trading risks that make ALNA stock a high-volatility, speculative idea in the United States (USD).

Pre-market price action and volume for ALNA stock

ALNA stock opened pre-market at $0.064 after a previous close of $0.0727 and is near $0.075. The intraday range shows a day low $0.06 and day high $0.1459, reflecting wide swings. Reported volume 252,311,606 shares is the primary reason ALNA appears among most-active names this session. One-day change is +3.16%, which reflects large block trades and retail interest rather than stable fundamentals.

Business summary and pipeline context for Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. (ALNA) is a small biotechnology company developing oral enzyme therapeutics, notably ALLN-346 for hyperuricemia and gout in advanced chronic kidney disease. The company is headquartered in Newton, Massachusetts, and operates in the Healthcare sector under Biotechnology. With about 12 full-time employees, ALNA remains a clinical-stage developer where news flow, trial readouts, and regulatory updates typically drive price moves rather than revenue.

Financial snapshot and key ratios affecting ALNA stock valuation

Financials show an EPS of -0.638 and a PE ratio that is negative at roughly -0.12, reflecting losses. Book value per share is $0.58 and cash per share is $0.92, supporting a current ratio of 2.11, which indicates short-term liquidity. Price-to-book sits near 0.13, suggesting the market values the stock below book. Enterprise value is reported negative due to cash offsets. These metrics show cash runway and balance-sheet strengths but continuing operating losses.

Technical view, trading risks and sector context for ALNA stock

Technically, ALNA displays extreme volatility—day range and high volume point to short-term trading setups, not long-term confirmation. Risks include thin public float, uncertain trial timelines, and limited institutional coverage. In the Biotechnology sector, small-cap clinical names often move on headline risk; sector performance can amplify ALNA stock swings. Traders should expect rapid percentage moves and low liquidity at tighter price bands.

Meyka AI grade and ALNA forecast analysis

Meyka AI rates ALNA with a score out of 100: 62.59 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, analyst consensus, and fundamentals. Meyka AI’s forecast model projects a 12-month base case price of $0.12, a bull case $0.30, and a bear case $0.03. Relative to the current $0.075, those imply +60.00%, +300.00%, and -60.00% moves respectively. Forecasts are model-based projections and not guarantees. See more on the company site and our ALNA page for updates ALNA on Meyka.

News, catalysts and where to watch for updates

ALNA trading spikes typically follow clinical updates, partnership announcements, or funding moves. For broad market news and biotech sector activity consult Reuters and MarketWatch; those outlets can flag macro or industry catalysts that affect ALNA stock liquidity and sentiment source source.

Final Thoughts

Key takeaways: ALNA stock is a pre-market most-active microcap with $0.075 pricing and 252,311,606 shares traded, driven by headline sensitivity and speculative flows. Balance-sheet metrics—cash per share $0.92 and current ratio 2.11—offer short-term support, while EPS -0.638 and negative PE reflect ongoing losses. Meyka AI’s forecast model projects a 12-month base case of $0.12 (implied +60.00%), a bull case $0.30 (+300.00%), and a bear case $0.03 (-60.00%). These scenarios highlight wide outcome dispersion and high risk-reward. Traders should treat ALNA as a high-volatility biotech trade, watch clinical or financing headlines closely, and consider position sizing and liquidity limits. Meyka AI, an AI-powered market analysis platform, will update this outlook as new data arrives. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.